Aigen Investment Management LP Takes $1.36 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Aigen Investment Management LP recently acquired 12,098 shares of Gilead Sciences, valued at approximately $1.36 million, indicating strong institutional interest in the biopharmaceutical company.
• Gilead Sciences reported an earnings per share (EPS) of $2.01 for the last quarter, surpassing analysts' expectations of $1.96, with a revenue of $7.08 billion, marking a 1.4% increase from the previous year.
• The company announced a quarterly dividend of $0.79 per share, reflecting an annualized payout of $3.16 and a dividend yield of 2.6%, which is supported by a payout ratio of 62.95%.

Aigen Investment Management LP purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,098 shares of the biopharmaceutical company's stock, valued at approximately $1,356,000.

A number of other large investors have also made changes to their positions in the stock. Cooper Financial Group purchased a new stake in shares of Gilead Sciences in the first quarter valued at approximately $262,000. American Alpha Advisors LLC purchased a new position in Gilead Sciences in the first quarter worth approximately $411,000. Atlas Capital Advisors Inc. boosted its position in shares of Gilead Sciences by 17.4% during the first quarter. Atlas Capital Advisors Inc. now owns 10,147 shares of the biopharmaceutical company's stock worth $1,137,000 after buying an additional 1,505 shares during the period. Berger Financial Group Inc purchased a new position in shares of Gilead Sciences during the first quarter worth $6,867,000. Finally, Pandora Wealth Inc. purchased a new position in shares of Gilead Sciences during the first quarter worth $2,577,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the transaction, the chief financial officer owned 162,610 shares of the company's stock, valued at $18,054,588.30. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares in the company, valued at approximately $68,006,826.25. This represents a 1.60% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 82,000 shares of company stock worth $8,984,175. Corporate insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on GILD. UBS Group raised their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Oppenheimer reduced their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Finally, Royal Bank Of Canada increased their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $114.82.

Gilead Sciences Stock Performance

Shares of GILD traded down $0.45 during midday trading on Tuesday, reaching $120.02. 6,084,059 shares of the stock were exchanged, compared to its average volume of 6,236,199. The business's 50-day moving average price is $111.37 and its 200 day moving average price is $107.91. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a twelve month low of $72.67 and a twelve month high of $121.83. The company has a market capitalization of $148.92 billion, a price-to-earnings ratio of 23.91, a PEG ratio of 0.76 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the company posted $2.01 earnings per share. The business's revenue was up 1.4% on a year-over-year basis. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.